Phaseline

Companies › Cocrystal Pharma

Cocrystal Pharma: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Infectious disease.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CDI-988
Norovirus antiviral
–Phase 1Norovirus–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07198139CDI-988Phase 1NorovirusInfectious diseaseSep 2026

From the company's SEC filings

Cash of $2m on 2026-06-30; operating cash outflow about $10m a year; runway about 3 months at that burn, to Sep 2026

Press releases filed as 8-K in the last year:

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.